Sangamo Biosciences (SGMO) Tops Q4 EPS by 11c

Sangamo Biosciences (NASDAQ: SGMO) reported Q4 EPS of ($0.14), $0.11 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $8.9 million versus the consensus estimate of $3.91 million.

For earnings history and earnings-related data on Sangamo Biosciences (SGMO) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss of $0.75/sh
• Barclays says AI trade is maturing, favors greater diversification